Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Ketalar — KETALAR
Application NDA016812 (NDA)
Dantrium — DANTRIUM
Application NDA018264 (NDA)
Dantrium — DANTRIUM
Application NDA017443 (NDA)
Nubain — NUBAIN
Application NDA018024 (NDA)
Tigan — TIGAN
Application NDA017530 (NDA)
Propylthiouracil — PROPYLTHIOURACIL
Application NDA006213 (NDA)
Propylthiouracil — PROPYLTHIOURACIL
Application NDA006188 (NDA)
Coly-Mycin M — COLY-MYCIN M
Application NDA050108 (NDA)
Brevital Sodium — BREVITAL SODIUM
Application NDA011559 (NDA)
Nubain — NALBUPHINE HYDROCHLORIDE
Application NDA020200 (NDA)
Tigan — TIGAN
Application NDA017531 (NDA)
Mucinex — MUCINEX
Application NDA021282 (NDA)
Dantrium — RYANODEX
Application NDA205579 (NDA)
Pitressin — VASOSTRICT
Application NDA204485 (NDA)
Pitressin — VASOPRESSIN
Application NDA212593 (NDA)
Pitressin — VASOPRESSIN IN SODIUM CHLORIDE 0.9%
Application NDA217569 (NDA)
Rapiblyk — RAPIBLYK
Application NDA217202 (NDA)
Pitressin — VASOPRESSIN IN SODIUM CHLORIDE 0.9%
Application NDA217766 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)